Clinical experience with adenovirus in cancer therapy

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 5, 2002, Pages 423-434

  Palmer, Daniel H ^a   Mautner, Vivien ^a   Kerr, David J ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Adenovirus; Cancer; Clinical trials; Gene therapy; Oncolytic virus

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ADVEXIN; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CARBOXYLESTERASE; CARBOXYPEPTIDASE G2; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; FLOXURIDINE; FLUCYTOSINE; FLUOROURACIL; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; HLA B7 ANTIGEN; IFOSFAMIDE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; IRINOTECAN; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; NITROREDUCTASE; ONCOLYTIC VIRUS; ONYX 015; PROTEIN P53; RETINOIC ACID; SCH 58500; THYMIDINE KINASE; UNINDEXED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE; VIRUS VECTOR;

ACCURACY; ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; EXPERIENCE; FEVER; FLU LIKE SYNDROME; GENE TARGETING; GENE THERAPY; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOGENETICS; IMMUNOSTIMULATION; LIVER CANCER; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS;

ADENOVIRIDAE; SIMPLEXVIRUS;

EID: 0036820266     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Journal of Gene Medicine website. Wiley, UK. http://www.wiley.co.uk/wileychi/genmed
2. Gene Therapy Advisory Committee website. Department of Health, UK. http://www.doh.gov.uk/genetics/gtac/
3. Romano G, Pacilio C, Giordano A: Gone transfer technology in therapy: Current applications and future goals. Stem Cells (1999) 17(4):191-202.
4. Dyer MR, Herrling PL: Progress and potential for gene-based medicines. Mol Ther (2000) 1(3):213-224.
5. Sobol RE, Shawler DL, Carson C, Van Beveren C, Mercola D, Fakhrai H, Garrett MA, Barone R, Goldfarb P, Bartholomew RM, Brostoff S et al: Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A phase I study. Clin Cancer Res (1999) 5(9):2359-2365.
6. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 275(5304):1320-1323.
7. Arnberg N, Edlund K, Kidd AH, Wadell G: Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol (2000) 74(1):42-48.
8. 5 promote adenovirus internalization but not virus attachment. Cell (1993) 73(2):309-319.
9. Greber UF, Willetts M, Webster P, Helenius A: Stepwise dismantling of adenovirus 2 during entry into cells. Cell (1993) 75(3):477-486.
10. Horwitz MS: Adenoviruses. In: Fields Virology, 4th Edition. Knipe DM, Howley PM et al (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001).
11. Graham FL, Prevec L: Manipulation of adenovirus vectors. In: Methods in Molecular Biology. Murray EJ, Clifton NJ (Eds), Humana Press Inc, NJ, USA (1991):109-128.
12. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS: Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol (1998) 72(2):926-933.
13. Kochanek S: High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther (1999) 10(15):2451-2459.
14. Russell WC: Update on adenovirus and its vectors. J Gen Virol (2000) 81(Pt 11):2573-2604.
15. Steinwaerder DS, Carlson CA, Lieber A: Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats. J Virol (1999) 73(11):9303-9313.
16. Reynolds PN, Feng M, Curiel DT: Chimeric viral vectors - the best of both worlds? Mol Med Today (1999) 5(1):25-31.
17. Todryk SM, Chong H, Vile RG, Pandha H, Lemoine NR: Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut (1998) 43(4):445-449.
18. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Failure of cancer vaccines: The significant limitations of this approach to immunotherapy. Anticancer Res (2000) 20(4):2665-2676.
19. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE: Cytokine gene therapy with interleukin-2-transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther (1995) 6(5):591-601.
20. Suminami Y, Elder EM, Lotze MT, Whiteside TL: In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother Emphasis Tumor Immunol (1995) 17(4):238-248.
21. Geutskens SB, van der Eb MM, Plomp AC, Jonges LE, Cramer SJ, Ensink NG, Kuppen PJ, Hoeben RC: Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther (2000) 7(16):1410-1416.
22. Putzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL: Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA (1997) 94(20):10889-10894.
23. Ostrand-Rosenberg S, Thakur A, Clements V: Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol (1990) 144(10):4068-4071.
24. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA (1993) 90(23):11307-11311.
25. Gonzalez R, Atkins M, Schwarzenberger P, Lutzky J, Rubin J, Deisseroth A, Blum A, Gutheil J, Hutchins L: Phase II trial of HLA-B7 plasmid DNA/lipid (Allovectin) immunotherapy in patients with metastatic melanoma. Proc Am Soc Clin Oncol (2001) 20:Abs 1007.
26. Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, Gregory RJ, Shepard HM, Maneval DC: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther (1996) 3(2):121-130.
27. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA: Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res (1998) 58(11):2288-2292.
28. Venook AP, Bergsland EK, Ring E, Nonaka-Wong S, Horowitz JA, Rybak ME, Warren RS: Gene therapy of colorectal liver metastasis using recombinant adenovirus encoding wt p53 (SCH 58500) via hepatic artery infusion: A phase I study. Proc Am Soc Clin Oncol (1998) 17:Abs 1661.
29. Cohen AM, Kemeny NE, Kohne CH, Wils J, de Takats PG, Kerr DJ: Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? Eur J Cancer (1996) 32A(13):2195-2205.
30. Hao D, Rowinsky EK, Smetzer LA, Ochoa L, Hammond LA, Garner A, Smith L, Parker K, Merritt JA, Tolcher AW: A phase I and pharmacokinetic study of intravenous (IV) p53 gene therapy with RPR/INGN-201 in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol (2001) 20:Abs 1045.
31. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA: Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg (1996) 112(5):1372-1376.
32. Roth JA, Swisher SG, Meyn RE: p53 tumor suppressor gene therapy for cancer. Oncology (1999) 13(10 Suppl 5):148-154.
33. Jiang GL, Huang S: Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers. Cancer Res (2001) 61(5):1796-1798.
34. Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Sakamoto T, Yoshiji H, Fukui H, Ikenaka K, Mullen CA, Tsujii T: Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int J Cancer (1999) 81(4):592-597.
35. Link CJ Jr, Levy JP, McCann LZ, Moorman DW: Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. J Surg Oncol (1997) 64(4):289-294.
36. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P et al: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther (2000) 11(16):2197-2205.
37. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, Woo SL: Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial. Mol Ther (2001) 4(3):182-191.
38. Huber BE, Austin EA, Richards CA, Davis ST, Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA (1994) 91(17):8302-8306.
39. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF, Kerr DJ: In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther (2001) 8(20):1547-1554.
40. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, Yankelevitz D, Kemeny N, Silverstein R, Ohwada A, Russi T et al: Phase I study of direct administration of a replication deficient adenovirus vector containing the E coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther (1997) 8(8):985-1001.
41. Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, Anlezark GM, Michael NP, Melton RG, Ford MJ, Young LS et al: Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E coli nitroreductase gene. Cancer Gene Ther (1997) 4(4):229-238.
42. Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P, Seymour L, Harris PA et al: Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res (2001) 7(9):2662-2668.
43. Palmer DH, Mautner V, Mirza D et al: Virus-directed enzyme prodrug therapy (VDEPT): Clinical trials with adenoviral nitroimidazole reductase (ad-ntr). Br J Cancer (2002) 86 (Suppl 1):530.
44. Chang TK, Weber GF, Crespi CL, Waxman DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res (1993) 53(23):5629-5637.
45. Marais R, Spooner RA, Light Y, Martin J, Springer CJ: Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res (1996) 56(20):4735-4742.
46. Kojima A, Hackett NR, Ohwada A, Crystal RG: In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest (1998) 101(8):1789-1796.
47. Lohr M, Hoffmeyer A, Kroger J, Freund M, Hain J, Holle A, Karle P, Knofel WT, Liebe S, Muller P, Nizze H et al: Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet (2001) 357(9268):1591-1592.
48. Rogulski KR, Kim JH, Kim SH, Freytag SO: Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther (1997) 8(1):73-85.
49. Ju DW, Wang BM, Cao X: Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity. J Cancer Res Clin Oncol (1998) 124(12):683-689.
50. Smith ER, Chiocca EA: Oncolytic viruses as novel anticancer agents: Turning one scourge against another. Expert Opin Investig Drugs (2000) 9(2):311-327
51. Wildner O, Blaese RM, Morris JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res (1999) 59(2):410-413.
52. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274(5286):373-376.
53. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p63 status in tumor cells. J Virol (1998) 72(12):9470-9478.
54. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med (2000) 6(10):1128-1133.
55. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kim D: Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther (2001) 8(21):1618-1626.
56. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M, Vernon CC, Gueret-Wardle D, El-Masry R, Salama H, Ahmed R et al: E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther (2001) 12(3):219-226.
57. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 6(8):879-885.
58. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kim D: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med (2000) 6(10):1134-1139.
59. Carroll NM, Chase M, Chiocca EA, Tanabe KK: The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res (1997) 69(2):413-417.
60. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther (2000) 11(1):67-76.
61. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, Whitley RJ: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther (1998) 5(1):121-130.
62. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B, Weichselbaum RR: Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther (1998) 5(2):160-165.
63. Komberg RD, Lorch Y: Chromatin-modifying and -remodeling complexes. Curr Opin Genet Dev (1999) 9(2):148-151.
64. Gaetano C, Catalano A, Palumbo R, Illi B, Orlando G, Ventoruzzo G, Serino F, Capogrossi MC: Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Ther (2000) 7(19):1624-1630.
65. Vile RG, Russell SJ, Lemoine NR: Cancer gene therapy: Hard lessons and new courses. Gene Ther (2000) 7(1):2-8.
66. Miller N, Whelan J: Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther (1997) 8(7):803-815.
67. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK: An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J (2000) 14(2):301-311.
68. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol (1996) 14(11):1574-1578.
69. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Kamen BA: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res (1992) 52(12):3396-3401.
70. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther (2001) 8(5):341-348.
71. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML: Construction of adenovirus vectors through Cre-lox recombination. J Virol (1997) 71(3):1842-1849.
72. Zhang WW: Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther (1999) 6(2):113-138.
73. Alemany R, Lai S, Lou YC, Jan HY, Fang X, Zhang WW: Complementary adenoviral vectors for oncolysis. Cancer Gene Ther (1999) 6(1):21-25.
74. Bartlett JS, Samulski RJ: Fluorescent viral vectors: A new technique for the pharmacological analysis of gene therapy. Nat Med (1998) 4(5):635-637.